Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

R. Doody · SciRah

Researcher profile · Semantic Scholar

R. Doody

Share profile

R. Doody — researcher profile on SciRah

h-index: 84
Works: 457
Citations: 44K

Most-cited papers

New insights into the genetic etiology of Alzheimer’s disease and related dementias
C. Bellenguez, F. Küçükali, I. Jansen, L. Kleineidam +496 more
2022Nature Genetics1,984 citations Open access
Semantic Scholar
Multi-ancestry genome-wide meta-analysis of 56,241 individuals identifies LRRC4C, LHX5-AS1 and nominates ancestry-specific loci PTPRK, GRB14, and KIAA0825 as novel risk loci for Alzheimer disease: the Alzheimer Disease Genetics Consortium
F. Rajabli, Penelope H. Benchek, G. Tosto, Nicholas A. Kushch +267 more
2023medRxiv1,124 citations Open access
Semantic Scholar
Trial of Prasinezumab in Early-Stage Parkinson's Disease.
G. Pagano, K. Taylor, J. Anzures‐Cabrera, M. Marchesi +41 more
2022New England Journal of Medicine300 citations Open access
Semantic Scholar
A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer’s disease
S. Salloway, M. Farlow, E. McDade, D. Clifford +61 more
2021Nature Medicine298 citations Open access
Semantic Scholar
Two Phase 3 Trials of Gantenerumab in Early Alzheimer’s Disease
R. Bateman, Janice Smith, M. Donohue, Paul Delmar +21 more
2023New England Journal of Medicine218 citations Open access
Semantic Scholar
Evaluating the Safety and Efficacy of Crenezumab vs Placebo in Adults With Early Alzheimer Disease
S. Ostrowitzki, T. Bittner, K. Sink, H. Mackey +23 more
2022JAMA Neurology167 citations Open access
Semantic Scholar
Prasinezumab slows motor progression in rapidly progressing early-stage Parkinson’s disease
G. Pagano, K. Taylor, Judith Anzures Cabrera, T. Simuni +14 more
2024Nature Medicine125 citations Open access
Semantic Scholar
Establishing Clinically Meaningful Change on Outcome Assessments Frequently Used in Trials of Mild Cognitive Impairment Due to Alzheimer’s Disease
C. Lansdall, F. Mcdougall, L. Butler, P. Delmar +6 more
2022The journal of prevention of Alzheimer's disease85 citations Open access
Semantic Scholar
Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer’s disease
R. Bateman, J. Cummings, S. Schobel, S. Salloway +9 more
2022Alzheimer's Research & Therapy82 citations Open access
Semantic Scholar
A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline Data
G. Pagano, F. Boess, K. Taylor, Benedicte Ricci +22 more
2021Frontiers in Neurology77 citations Open access
Semantic Scholar
Tominersen in Adults with Manifest Huntington's Disease.
P. McColgan, A. Thobhani, L. Boak, S. Schobel +19 more
2023New England Journal of Medicine76 citations Open access
Semantic Scholar
Sustained effect of prasinezumab on Parkinson’s disease motor progression in the open-label extension of the PASADENA trial
G. Pagano, Annabelle Monnet, Adriana Reyes, Benjamin Ribba +16 more
2024Nature Medicine62 citations Open access
Semantic Scholar
Deep learning-based polygenic risk analysis for Alzheimer’s disease prediction
Xiao-Pu Zhou, Yu Chen, Fanny C. F. Ip, Yuanbing Jiang +322 more
2023Communications Medicine60 citations Open access
Semantic Scholar
Amyloid-Related Imaging Abnormalities (ARIA) in Clinical Trials of Gantenerumab in Early Alzheimer Disease
S. Salloway, J. Wojtowicz, N. Voyle, C. Lane +13 more
2024JAMA Neurology55 citations Open access
Semantic Scholar
Thirty-Six-Month Amyloid Positron Emission Tomography Results Show Continued Reduction in Amyloid Burden with Subcutaneous Gantenerumab
G. Klein, P. Delmar, G. Kerchner, C. Hofmann +6 more
2020The journal of prevention of Alzheimer's disease52 citations Open access
Semantic Scholar
Dissociation of tau pathology and neuronal hypometabolism within the ATN framework of Alzheimer’s disease
M. T. Duong, Sandhitsu R. Das, Xueying Lyu, Long Xie +286 more
2022Nature Communications44 citations Open access
Semantic Scholar
Longitudinal Sensitivity of Alzheimer’s Disease Severity Staging
Julia S. Benoit, W. Chan, L. Piller, R. Doody
2020American Journal of Alzheimers Disease & Other Dementias36 citations Open access
Semantic Scholar
Platform Trials to Expedite Drug Development in Alzheimer's Disease: A Report from the EU/US CTAD Task Force
P. Aisen, R. Bateman, M. Carrillo, R. Doody +4 more
2021The journal of prevention of Alzheimer's disease31 citations Open access
Semantic Scholar
Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer’s disease: an open label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU Trial
Randall J. Bateman, Yan Li, E. McDade, J. Llibre-Guerra +64 more
2024medRxiv30 citations Open access
Semantic Scholar
Higher CSF sTNFR1-related proteins associate with better prognosis in very early Alzheimer’s disease
William T. Hu, T. Ozturk, Alexander L. Kollhoff, W. Wharton +168 more
2021Nature Communications30 citations Open access
Semantic Scholar
A novel spatiotemporal graph convolutional network framework for functional connectivity biomarkers identification of Alzheimer’s disease
Ying Zhang, Le Xue, Shuoyan Zhang, Jiacheng Yang +309 more
2024Alzheimer's Research & Therapy27 citations Open access
Semantic Scholar
Manifestations of Alzheimer’s disease genetic risk in the blood are evident in a multiomic analysis in healthy adults aged 18 to 90
Laura M. Heath, J. Earls, A. Magis, S. Kornilov +195 more
2022Scientific Reports24 citations Open access
Semantic Scholar
Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer’s disease: an open label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU Trial
Randall J. Bateman, Yan Li, E. McDade, J. Llibre-Guerra +64 more
2025Lancet Neurology22 citations Open access
Semantic Scholar
Multi-ancestry genome-wide meta-analysis of 56,241 individuals identifies known and novel cross-population and ancestry-specific associations as novel risk loci for Alzheimer’s disease
F. Rajabli, Penelope H. Benchek, G. Tosto, Nicholas A. Kushch +282 more
2025Genome Biology22 citations Open access
Semantic Scholar
A Phase 2b, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of intravenous prasinezumab in early-stage Parkinson's disease (PADOVA): Rationale, design, and baseline data.
T. Nikolcheva, G. Pagano, Nathalie Pross, T. Simuni +17 more
2024Parkinsonism & Related Disorders21 citations Open access
Semantic Scholar
Neuropsychiatric Symptoms in AD: Clinical Trials Targeting Mild Behavioral Impairment: A Report from the International CTAD Task Force
Maria Soto, P. Rosenberg, C. Ballard, B. Vellas +99 more
2023The journal of prevention of Alzheimer's disease21 citations Open access
Semantic Scholar
Clinical Meaningfulness in Alzheimer’s Disease Clinical Trials. A Report from the EU-US CTAD Task Force
D. Angioni, J. Cummings, C. Lansdall, L. Middleton +14 more
2024The journal of prevention of Alzheimer's disease20 citations Open access
Semantic Scholar
Chinese Version of the Baylor Profound Mental Status Examination: A Brief Staging Measure for Patients with Severe Alzheimer’s Disease
X. Fu, W. Yu, M. Ke, X. Wang +5 more
2020The journal of prevention of Alzheimer's disease19 citations Open access
Semantic Scholar
Can We Use Blood Biomarkers as Entry Criteria and for Monitoring Drug Treatment Effects in Clinical Trials? A Report from the EU/US CTAD Task Force
D. Angioni, O. Hansson, R. Bateman, C. Rabe +99 more
2023The journal of prevention of Alzheimer's disease18 citations Open access
Semantic Scholar
Connecting Cohorts to Diminish Alzheimer’s Disease (CONCORD-AD): A Report of an International Research Collaboration Network
V. Pavlik, S. Burnham, J. Kass, C. Helmer +13 more
2021Journal of Alzheimer's Disease18 citations Open access
Semantic Scholar
Racial and ethnic diversity in global neuroscience clinical trials
Loes Rutten-Jacobs, Tammy McIver, Adriana Reyes, M. Pereira +4 more
2024Contemporary Clinical Trials Communications17 citations Open access
Semantic Scholar
Therapeutic Targets for Alzheimer’s Disease: Amyloid Vs. Non-Amyloid. Where Does Consensus Lie Today? An CTAD Task Force Report
S. Gauthier, A. Boxer, D. Knopman, J. Sims +5 more
2022The journal of prevention of Alzheimer's disease15 citations Open access
Semantic Scholar
Promoting diversity in clinical trials: insights from planning the ALUMNI AD study in historically underrepresented US populations with early symptomatic Alzheimer's disease
Alexandria Wise-Brown, Sharon Brangman, J. Henderson, Monica Willis-Parker +10 more
2024EClinicalMedicine13 citations Open access
Semantic Scholar
Glucose metabolism in posterior cingulate cortex has supplementary value to predict the progression of cognitively unimpaired to dementia due to Alzheimer’s disease: an exploratory study of ^18F-FDG-PET
Qi Zhang, Chunqiu Fan, Lu-Yao Wang, Tao-Ran Li +306 more
2023GeroScience13 citations Open access
Semantic Scholar
Different Cognitive Profiles Are Associated with Progression Rate and Age at Death in Probable Alzheimer’s Disease
Ajay Sood, V. Pavlik, E. Darby, W. Chan +1 more
2021Journal of Alzheimer's Disease13 citations
Semantic Scholar
Exploratory digital outcome measures of motor sign progression in Parkinson’s disease patients treated with prasinezumab
K. Taylor, F. Lipsmeier, M. A. Scelsi, E. Volkova-Volkmar +308 more
2025npj Digital Medicine12 citations Open access
Semantic Scholar
Development of a quantitative semi‐mechanistic model of Alzheimer's disease based on the amyloid/tau/neurodegeneration framework (the Q‐ATN model)
N. Mazer, C. Hofmann, Dominik Lott, R. Gieschke +7 more
2022Alzheimer's & Dementia10 citations Open access
Semantic Scholar
Consensus meta-analysis of genome-wide association studies for Alzheimer’s disease and related dementias
Céline Atahualpa Najaf Sven J. Manon Kayenat Fahri Benjam Bellenguez Castillo Morales Amin van der Lee Munta, C. Bellenguez, Atahualpa Castillo Morales, N. Amin +496 more
2026Nature Genetics9 citations Open access
Semantic Scholar
GRADUATE I AND II: Findings of Two Phase III Randomized Placebo-controlled Studies Assessing the Efficacy and Safety of Subcutaneous Gantenerumab in Early Alzheimer’s Disease (AD) (S26.010)
Janice Smith, M. Donohue, E. Gruendl, T. Grimmer +13 more
2023Tuesday, April 259 citations
Semantic Scholar
Higher CSF sTREM2 attenuates ApoE4-related risk for cognitive decline and neurodegeneration
N. Franzmeier, M. Suárez-Calvet, Lukas Frontzkowski, Annah M. Moore +219 more
2020Molecular Neurodegeneration8 citations Open access
Semantic Scholar
Graduation study design: Evaluation of once‐weekly subcutaneous administration of gantenerumab on brain amyloid load
F. Boess, Shunsuke Sakaoka, D. Abi‐Saab, Marzia Antonella Scelsi +6 more
2021Alzheimer's & Dementia7 citations
Semantic Scholar
Long-Term Safety of Gantenerumab in Participants with Alzheimer’s Disease: A Phase III, Double-Blind, and Open-Label Extension Study (Marguerite RoAD)
A. Neve, Bibha Das, J. Wojtowicz, Zhi-Yue Huang +12 more
2024Journal of Alzheimer's Disease6 citations Open access
Semantic Scholar
At-home Administration of Gantenerumab by Care Partners to People with Early Alzheimer’s Disease: Feasibility, Safety and Pharmacodynamic Impact
Frank G. Boess, M. A. Scelsi, T. Grimmer, R. Perry +10 more
2024The journal of prevention of Alzheimer's disease5 citations Open access
Semantic Scholar
Using an external control to contextualize efficacy data from patients with prodromal and mild Alzheimer’s disease treated with gantenerumab in SCarlet RoAD and Marguerite RoAD open‐label extension studies
P. Delmar, Zhiyue Huang, A. Neve, G. Klein +4 more
2022Alzheimer's & Dementia5 citations
Semantic Scholar
Local molecular and connectomic contributions of tau-related neurodegeneration
F. Nabizadeh, Michael W. Weiner, P. Aisen, Ronald Petersen +300 more
2024GeroScience4 citations Open access
Semantic Scholar
Gantenerumab in Early Alzheimer's Disease. Reply.
R. Bateman, Janice Smith, R. Doody
2024New England Journal of Medicine4 citations
Semantic Scholar
Safety and efficacy of crenezumab in cognitively unimpaired carriers of the PSEN1Glu280Ala mutation at risk for autosomal-dominant Alzheimer’s disease in Colombia (API ADAD Colombia Trial): a phase 2, randomised, double-blind, placebo-controlled trial
P. Tariot, F. Lopera, S. Ríos‐Romenets, K. Sink +40 more
2026Lancet Neurology3 citations Open access
Semantic Scholar
Open RoAD: Design and baseline characteristics of an open‐label rollover study evaluating long‐term safety and tolerability of subcutaneous gantenerumab in participants with early Alzheimer’s disease
A. Neve, Szofia Bullain, Bibha Das, Zhiyue Huang +10 more
2023Alzheimer's & Dementia3 citations Open access
Semantic Scholar
PostGraduate Open-label Rollover Study: Evaluation of Subcutaneous Gantenerumab Long-term Safety, Tolerability, and Efficacy in Participants with Alzheimer’s Disease (P6-3.002)
C. Lane, A. Thanasopoulou, Paul Delmar, Alison Searle +6 more
2022Neurology3 citations
Semantic Scholar
Gantenerumab treatment increases plasma beta‐amyloid(1–42) and decreases plasma pTau
T. Bittner, Marzia A. Scelsi, G. Kollmorgen, A. Jethwa +4 more
2022Alzheimer's & Dementia3 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

G. Kerchner×16
Invite
G. Kerchner — researcher profile on SciRah
L. Honig×13
Invite
L. Honig — researcher profile on SciRah
A. Levey×13
Invite
A. Levey — researcher profile on SciRah
S. Salloway×13
Invite
S. Salloway — researcher profile on SciRah

×12

Invite

M. Farlow — researcher profile on SciRah

Invite

J. Lah — researcher profile on SciRah

E. Roberson×12

Invite

E. Roberson — researcher profile on SciRah

Invite

P. Aisen — researcher profile on SciRah

Invite

M. Baudler — researcher profile on SciRah

Invite

T. Foroud — researcher profile on SciRah

C. Carlsson×11

Invite

C. Carlsson — researcher profile on SciRah

Invite

R. Duara — researcher profile on SciRah